title: A safe immunosuppressive protocol in adult-to-adult living related liver transplantation.
abstract: BACKGROUND
  In this series of 32 adult-to-adult living related liver transplantations, we assessed the efficacy and safety of basiliximab in combination with a tacrolimus-based regimen. Basiliximab, a chimeric monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor (CD25), has been extensively evaluated as induction therapy for cadaveric liver transplant recipients.
  
  
  METHODS
  Thirty-two adult-to-adult living related liver transplantations were performed in the last 3 years. All patients received two 20 mg doses of basiliximab (days 0 and 4 posttransplantation) followed by tacrolimus (0.15 mg/kg/d; 10-15 ng/mL target trough levels) and steroids (starting with 20 mg IV switched to PO as soon as the patient was able to eat and weaned within 1-2 months). The average follow-up was 395 days after transplantation.
  
  
  RESULTS
  Of the patients, 93.75% remained rejection-free during follow-up with an actuarial rejection-free probability of 92.59% within 3 months. Two patients (6%) had one episode of biopsy-proven acute cellular rejection (ACR). Actuarial patient and graft survival rates at 3 years were 86.85% and 81.25%. One patient (3%) experienced one episode of sepsis. There was no evidence of cytomegalovirus infections or side effects related to the basiliximab. We found zero de novo malignancy but we observed two patients with metastatic spread of their primary malignancy during the follow-up.
  
  
  CONCLUSIONS
  Basiliximab in association with tacrolimus and steroids is effective as prophylaxis of ACR among adult living related liver transplant recipients.
authors.affiliation: Istituto Mediterraneo Trapianti e Terapie ad Atta Specializzazione (IsMeTT), Italy, Palermo. sgruttadauria@ismett.edu
authors.forename: S
authors.initials: S
authors.lastname: Gruttadauria
authors.forename: D
authors.initials: D
authors.lastname: Cintorino
authors.forename: T
authors.initials: T
authors.lastname: Piazza
authors.forename: L
authors.initials: L
authors.lastname: Mandala
authors.forename: E
authors.initials: E
authors.lastname: Doffria
authors.forename: A
authors.initials: A
authors.lastname: Musumeci
authors.forename: G
authors.initials: G
authors.lastname: Di Trapani
authors.forename: A
authors.initials: A
authors.lastname: Arcadipane
authors.forename: G
authors.initials: G
authors.lastname: Scianna
authors.forename: M
authors.initials: M
authors.lastname: Spada
authors.forename: R
authors.initials: R
authors.lastname: Verzaro
authors.forename: R
authors.initials: R
authors.lastname: Volpes
authors.forename: G
authors.initials: G
authors.lastname: Vizzini
authors.forename: U
authors.initials: U
authors.lastname: Palazzo
authors.forename: M
authors.initials: M
authors.lastname: Minervini
authors.forename: J W
authors.initials: JW
authors.lastname: Marsh
authors.forename: A
authors.initials: A
authors.lastname: Marcos
authors.forename: B
authors.initials: B
authors.lastname: Gridelli
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005190:Family; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000209:etiology / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012449:Safety; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D016559:Tacrolimus